5/27
07:44 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) shareholders have endured a 15% loss from investing in the stock a year ago [Yahoo! Finance]
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) shareholders have endured a 15% loss from investing in the stock a year ago [Yahoo! Finance]
5/24
01:21 pm
bmrn
BioMarin (BMRN) Down 7.6% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
Low
Report
BioMarin (BMRN) Down 7.6% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
5/18
06:25 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.
5/17
07:44 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $72.00 price target on the stock, down previously from $104.00.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $72.00 price target on the stock, down previously from $104.00.
5/14
05:51 pm
bmrn
BioMarin Pharmaceutical to lay off 170 employees [Seeking Alpha]
Low
Report
BioMarin Pharmaceutical to lay off 170 employees [Seeking Alpha]
5/14
08:01 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $113.00 price target on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $113.00 price target on the stock.
5/8
08:05 am
bmrn
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV [Yahoo! Finance]
Low
Report
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV [Yahoo! Finance]
5/8
08:00 am
bmrn
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
Low
Report
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
5/4
04:03 pm
bmrn
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting [Yahoo! Finance]
Low
Report
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting [Yahoo! Finance]
5/4
04:00 pm
bmrn
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
Low
Report
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
4/30
06:33 am
bmrn
BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year [Yahoo! Finance]
Low
Report
BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year [Yahoo! Finance]
4/27
05:10 am
bmrn
4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market [Yahoo! Finance]
Low
Report
4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market [Yahoo! Finance]
4/26
01:39 pm
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Morgan Stanley from $115.00 to $112.00. They now have an "overweight" rating on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Morgan Stanley from $115.00 to $112.00. They now have an "overweight" rating on the stock.
4/26
09:08 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $91.00 to $89.00. They now have a "hold" rating on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $91.00 to $89.00. They now have a "hold" rating on the stock.
4/26
09:04 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
4/26
07:27 am
bmrn
Global Cell and Gene Therapies in Hemophilia A & B Analysis Report 2024: Market to Reach $2.2 Billion by 2029 - Major Players Are Expected To Intensify Competition [Yahoo! Finance]
Low
Report
Global Cell and Gene Therapies in Hemophilia A & B Analysis Report 2024: Market to Reach $2.2 Billion by 2029 - Major Players Are Expected To Intensify Competition [Yahoo! Finance]
4/25
07:14 pm
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Citigroup Inc. from $94.00 to $91.00. They now have a "neutral" rating on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Citigroup Inc. from $94.00 to $91.00. They now have a "neutral" rating on the stock.
4/25
03:51 pm
bmrn
BioMarin stock falls 9% in wake of Q1 report, pipeline updates [Seeking Alpha]
Low
Report
BioMarin stock falls 9% in wake of Q1 report, pipeline updates [Seeking Alpha]
4/25
01:40 pm
bmrn
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales [Yahoo! Finance]
Low
Report
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales [Yahoo! Finance]
4/25
12:03 pm
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Scotiabank from $83.00 to $85.00. They now have a "sector perform" rating on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Scotiabank from $83.00 to $85.00. They now have a "sector perform" rating on the stock.
4/25
11:21 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
4/25
10:24 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Wells Fargo & Company from $100.00 to $110.00. They now have an "overweight" rating on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Wells Fargo & Company from $100.00 to $110.00. They now have an "overweight" rating on the stock.
4/24
08:31 pm
bmrn
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]
Medium
Report
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]
4/24
06:23 pm
bmrn
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates [Yahoo! Finance]
Medium
Report
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates [Yahoo! Finance]
4/24
05:25 pm
bmrn
BioMarin updated 2024 guidance sees EPS raise, but no change to revenue [Seeking Alpha]
Medium
Report
BioMarin updated 2024 guidance sees EPS raise, but no change to revenue [Seeking Alpha]